Biomarker Discovery Solutions ImmunoID NeXT™ for Tumor Immunogenomics Elucidate Tumor-Immune Interactions from a Single Sample In the immuno-oncology era, it’s becoming clear that understanding and improving response to cancer immunotherapies relies on the study of the interactions between tumor cells and immune cells in the Tumor Microenvironment (TME). Traditionally, gaining molecular [...]
Genomics Solutions for Neoantigen Based Cancer Therapies High quality, comprehensive genomic data and analytics for personalized cancer therapy development Enabling Truly Personalized Neoantigen Based Cancer Therapies The first step of developing personalized cancer therapeutics is the identification of patient-specific neoantigens. With ImmunoID NeXT™, our partners can utilize our proprietary [...]
This online seminar will outline a target enrichment technology to improve next generation sequencing assays for cancer research.
GenomeWeb: Comprehensive Tumor Characterization for Immuno Oncology, Clinical Trials, and Cancer Research This GenomeWeb seminar outlines a targeted enrichment technology to improve next-generation sequencing assays for cancer research and clinical applications. Presenters: Richard Chen, MD and Michael James Clark, PhD More Info: NGS is increasingly being used to support cancer clinical trials, translational [...]
NGS-based Tumor Profiling: Lab, Clinic & Patient Perspectives This presentation covers comprehensive tumor characterization solutions for clinical trials, cancer research and immune-oncology, including: specific challenges in sequencing and analyzing tumors for neoantigen identification; key differentiators of the ACE IThree speakers from NSGC’s Annual Education Conference 2016 present key challenges associated with NGS-based tumor [...]
Tumor Characterization Solutions for Clinical Trials, Cancer Research & Immuno-Oncology This presentation covers comprehensive tumor characterization solutions for clinical trials, cancer research and immune-oncology, including: specific challenges in sequencing and analyzing tumors for neoantigen identification; key differentiators of the ACE ImmunoID as compared to standard NGS offerings; and a review of the technical [...]
NGS Best Practices for Developing Personalized Neoantigen Vaccines Precision medicine strategies have changed how the industry is approaching the development of cancer treatment vaccines, from targeting tumor-specific mutations to harnessing the power of the immune system. Advances in immuno-oncology research and next-generation sequencing (NGS) technologies has led to the discovery of a promising [...]
Labroots: Precision Genomics and Precision Medicine for Immuno Oncology Tumors often evade immune destruction by adapting and circumventing immune checkpoints to create resistance. This adaptive immunity can be reversed to stimulate the endogenous immune response. Extensive efforts using Immunotherapeutic approaches are currently being investigated for various cancer types to activate our immune system, [...]
Unlocking the potential of personalized neoantigen vaccines with ACE ImmunoID™ Cancer vaccine success has been limited, but neoantigen cancer vaccines are demonstrating considerable potential. Learn more about how Personalis can help you to accurately detect neoantigens to enable the development of safer, more effective vaccines.
Precision Genomics for Precision Medicine: Examples in Immuno-Oncology Richard Chen, Personalis - Stanford Medicine Big Data | Precision Health 2016. Bringing together thought leaders in large-scale data analysis and technology to transform the way we diagnose, treat and prevent disease.